Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the p38 mitogen-activated protein kinase pathway

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2043-2053

  Hui, Wang ^a   Litherland, Gary J ^a   Jefferson, Matthew ^a   Barter, Matt J ^a   Elias, Martina S ^a   Cawston, Tim E ^a   Rowan, Andrew D ^a   Young, David A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chondrocytes; Gene expression; Lithium; Osteoarthritis; P38

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; CYTOKINE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INTERLEUKIN 1; LITHIUM CHLORIDE; MATRIX METALLOPROTEINASE; ONCOSTATIN M; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT;

AGED; ANIMALS; CARTILAGE; CATTLE; CHONDROCYTES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LITHIUM CHLORIDE; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649390227     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq217     Document Type: Article

References (55)

1. Zhang W, Doherty M. How important are genetic factors in osteoarthritis? Contributions from family studies. J Rheumatol 2005;32:1139-42.
2. Dieude P, Cornelis F. Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005;72:520-6.
3. Brown MA. Antibody treatments of inflammatory arthritis. Curr Med Chem 2005;12:2943-6.
4. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res 339:221-35.
5. Rowan AD, Litherland GJ, Hui W, Milner JM. Metalloproteases as potential therapeutic targets in arthritis treatment. Expert Opin Ther Targets 2008;12:1-18.
6. Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun 1995;215:377-85.
7. Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 2003;48:3404-18.
8. Rowan AD, Hui W, Cawston TE, Richards CD. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol 2003;162:1975-84.
9. Rowan AD, Koshy PJ, Shingleton WD et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001;44:1620-32.
10. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004;S27-36.
11. Williams R, Ryves WJ, Dalton EC et al. A molecular cell biology of lithium. Biochem Soc Trans 2004;32:799-802.
12. Williams RS, Harwood AJ. Lithium therapy and signal transduction. Trends Pharmacol Sci 2000;21:61-4.
13. York JD, Ponder JW, Majerus PW. Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA 1995;92:5149-53.
14. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005;30:1223-37.
15. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274:6039-42.
16. Feinstein DL. Potentiation of astroglial nitric oxide synthase type-2 expression by lithium chloride. J Neurochem 1998;71:883-6.
17. Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology 1997;17:12-7.
18. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996;67:767-77.
19. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 2008;151:1184-97.
20. Cawston TE, Curry VA, Summers CA et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998;41:1760-71.
21. Milner JM, Rowan AD, Cawston TE, Young DA. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther 2006;8:R142.
22. Zhang Q, Hui W, Litherland GJ et al. Differential toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008;67:1633-41.
23. Koshy PJ, Rowan AD, Life PF, Cawston TE. 96-Well plate assays for measuring collagenase activity using (3)H-acetylated collagen. Anal Biochem 1999;275:202-7.
24. Cleaver CS, Rowan AD, Cawston TE. Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines. Ann Rheum Dis 2001;60:150-7.
25. Morgan TG, Rowan AD, Dickinson SC et al. Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases. Ann Rheum Dis 2006;65:184-90.
26. Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun 1995;215:377-85.
27. Hui W, Cawston T, Rowan AD. Transforming growth factor beta 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor alpha from bovine cartilage. Ann Rheum Dis 2003;62:172-4.
28. Liu S, Yu S, Hasegawa Y et al. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 2004;279:51075-81.
29. Pardo R, Andreolotti AG, Ramos B, Picatoste F, Claro E. Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem 2003;87:417-26.
30. Sproule B. Lithium in bipolar disorder: can drug concentrations predict therapeutic effect? Clin Pharmacokinet 2002;41:639-60.
31. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406:86-90.
32. Cuzzocrea S, Mazzon E, Di Paola R et al. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006;120:57-67.
33. Acharya JK, Labarca P, Delgado R, Jalink K, Zuker CS. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron 1998;20:1219-29.
34. Frederick JP, Tafari AT, Wu SM et al. A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation. Proc Natl Acad Sci USA 2008;105:11605-12.
35. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43:801-11.
36. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002;21:251-62.
37. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
38. Alford KA, Glennie S, Turrell BR, Rawlinson L, Saklatvala J, Dean JL. Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling. J Biol Chem 2007;282:6232-41.
39. Landry J, Lambert H, Zhou M et al. Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem 1992;267:794-803.
40. Rouse J, Cohen P, Trigon S et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994;78:1027-37.
41. Saklatvala J, Kaur P, Guesdon F. Phosphorylation of the small heat-shock protein is regulated by interleukin 1, tumour necrosis factor, growth factors, bradykinin and ATP. Biochem J 1991;277:635-42.
42. Jones SW, Brockbank SM, Clements KM et al. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology. Osteoarthr Cartil 2009;17:124-31.
43. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997;15:519-26.
44. Struewing IT, Durham SN, Barnett CD, Mao CD. Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J Biol Chem 2009;284:17595-606.
45. Badger AM, Roshak AK, Cook MN et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthr cartil 2000;8: 434-43.
46. Wada Y, Shimada K, Sugimoto K, Kimura T, Ushiyama S. Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metalloproteinase-1,-13 and prostaglandin E2 production in human chondrocytes. Int Immunopharmacol 2006;6: 144-55.
47. Nieminen R, Leinonen S, Lahti A et al. Inhibitors of mitogen-activated protein kinases downregulate COX-2 expression in human chondrocytes. Mediators Inflamm 2005;2005:249-55.
48. Underwood DC, Osborn RR, Kotzer CJ et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000;293:281-8.
49. Beardmore VA, Hinton HJ, Eftychi C et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 2005;25:10454-64.
50. Brown KK, Heitmeyer SA, Hookfin EB et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm 2008;5:22.
51. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL. Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61.
52. Badger AM, Griswold DE, Kapadia R et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83.
53. Cohen SB, Cheng TT, Chindalore V et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44.
54. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41.
55. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20. www.rheumatology.oxfordjournals.org 2053